Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
about
PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis.Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review.Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.High mobility group protein B1 is a predictor of poor survival in ovarian cancer.
P2860
Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
@en
type
label
Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
@en
prefLabel
Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
@en
P2093
P2860
P1476
Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer
@en
P2093
Eun Ji Nam
Jiheum Paek
Sang Wun Kim
Young Tae Kim
P2860
P2888
P304
P356
10.1007/S00404-015-3864-1
P50
P577
2015-08-25T00:00:00Z